{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Methotrexate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pentostatin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Rabbit anti-thymocyte globulin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Mycophenolate mofetil"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Tacrolimus"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Infliximab"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Etanercept"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Alemtuzumab"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Sirolimus"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Any systemic medication given in an effort to control graft-versus-host disease","groups":[{"description":"Patients received oral lithium carbonate once or twice daily. Treatment continued for up to 8 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treated Patients"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 100 days after enrollment","title":"Agents Added to Treat GVHD More Than 3 Days After Enrollment","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}